Motion Sickness Relief Dimenhydrinate 50 mg Tablet, 12-count
by Amerisource Bergen · 2 BLISTER PACK in 1 CARTON (46122-536-53) / 6 TABLET in 1 BLISTER PACK
NDC 46122-0536-53
🏷️ FDA NDC (as labeled)
46122-536-53
billing pads the product segment with a zero
OTC
On market
Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
🆔 Identity & classification
FDA NDC (as labeled)
46122-536-53
Product NDC
46122-536
11-digit billing NDC
46122053653
NCPDP billing unit
EA — each (per item)
RxCUI
198603
UNII
JB937PER5C
UPC
0346122536530
Application #
M009
SPL Set ID
c4077301-db6c-473d-beb3-232d7134a13a
Established class (EPC)
Histamine-1 Receptor Antagonist
Mechanism of action
Histamine H1 Receptor Antagonists
DEA schedule
Non-controlled
Marketing category
OTC MONOGRAPH DRUG
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
1992-12-01
Route
ORAL
Dosage form
TABLET
Substance
DIMENHYDRINATE
GPI-14
50200030000310
GPI class
GNP Motion Sickness Relief
GCN Seq No
004720
GCN
18231
HICL code
004603
Ingredient (HICL)
Dimenhydrinate
HIC1 code
H
Therapeutic class — broad (HIC1)
Nervous System (Except Autonomic)
HIC2 code
H6
Therapeutic class — intermediate (HIC2)
Drugs Acting Principally On The Midbrain
HIC3 code
H6J
Therapeutic class — specific (HIC3)
Antiemetic/Antivertigo Agents
AHFS code
04:04.00.00
AHFS class
First Generation Antihistamines
FDB label name
MOTION SICKNESS 50 MG TABLET
FDB brand name
Motion Sickness Relief
Legend status
O — Over-the-counter (OTC) drug or device
Why two NDCs?
The FDA registers this code as 46122-536-53 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 46122-0536-53. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏷️ RxNorm drug class
This medicine belongs to the Aminoalkyl ethers class.
Drug family (ATC)
Aminoalkyl ethers
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
🏭 Manufacturer & labeler
LabelerAmerisource Bergen
FDA applicationM009 (OTC MONOGRAPH DRUG)
Labeler code46122
First marketedDec 1992
Product typeHuman Otc Drug
Portfolio206 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
Label name MOTION SICKNESS 50 MG TABLET Ingredient Dimenhydrinate
📖 What it is MedlinePlus · NLM
Dimenhydrinate is used to prevent and treatmotion sickness. Dimenhydrinate is in a class of medications called antihistamines. It works by preventing problems with body balance.
Read the full MedlinePlus article ↗📗 Our plain-language guide HelloPharmacist
- Dimenhydrinate works by calming your inner ear when it gets overstimulated during travel — that's the root cause of the nausea, vomiting, and dizziness you feel. It's proven effect...
- What exactly does dimenhydrinate do — and will it stop my motion sickness?
- Drowsiness is the most common side effect — it's very real and something to plan for. Avoid driving or operating machinery until you know how dimenhydrinate affects you. Alcohol, s...
- It can be used in children as young as 2 years old — but only with a doctor's guidance for children under 2, and never in newborns. In young children especially, antihistamine over...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Dimenhydrinate — tap one for details:
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about Dimenhydrinate?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Color
white
ShapeRound
Imprint44;198
Size9 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII M28OL1HH48
Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
-
UNII O7TSZ97GEP
A mineral compound that serves as a filler and binding agent in tablets and capsules. It adds bulk to the medicine and helps hold ingredients together during manufacturing.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
-
UNII 4ELV7Z65AP
Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.
6 inactive ingredients listed in the exact product block matched to this NDC.
The official label also statescroscarmellose sodium, dibasic calcium phosphate dihydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, stearic acid
Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.058 | $0.69 / 12 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.5244 | $6.29 / 12 tablets |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
NADAC price history (per ea) — tap or hover for the price & month
▼ Down 1% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Dimenhydrinate 50 mg 70000-0404-01 | LEADER/ | 12 tablets | $0.054 | — | Availability likely | save 6% |
| Driminate 50 mg 00904-2051-59 | Major | 100 tablets | $0.058 | — | Availability likely | — |
| Dimenhydrinate 50 mg 00904-6772-12 | Major | 12 tablets | $0.058 | — | Availability likely | — |
| Motion Sickness Relief 50 mgthis 46122-0536-53 | Amerisource | 12 tablets | $0.058 | — | Availability likely | — |
| Motion Sickness Relief 50 mg 70000-0749-01 | Cardinal | 12 tablets | $0.058 | — | Availability likely | — |
| Motion Sickness 50 mg 70677-1087-01 | Strategic | 12 tablets | $0.058 | — | Availability likely | — |
| Motion Sickness Relief 50 mg 83324-0032-12 | Chain | 12 tablets | $0.058 | — | Availability likely | — |
| Motion Sickness Relief 50 mg 00363-1980-08 | Walgreen | 24 tablets | — | — | FDA listed | — |
| Gravol 50 mg 10237-0941-10 | Church | 10 tablets | — | — | FDA listed | — |
| Motion Sickness 50 mg 11673-0198-02 | Target | 12 tablets | — | — | FDA listed | — |
| Motion Sickness Relief 50 mg 11673-0354-24 | TARGET | 24 tablets | — | — | FDA listed | — |
| Motion Sickness Relief 50 mg 11822-0198-02 | Rite | 12 tablets | — | — | FDA listed | — |
| Motion Sickness Relief 50 mg 36800-0930-12 | Topco | 12 tablets | — | — | FDA listed | — |
| Motion Sickness Relief 50 mg 49035-0981-12 | Wal-Mart | 100 tablets | — | — | FDA listed | — |
| Motion Sickness 50 mg 50804-0198-02 | Geiss, | 12 tablets | — | — | FDA listed | — |
| Motion Sickness Relief 50 mg 50844-0199-02 | L.N.K. | 12 tablets | — | — | FDA listed | — |
| Motion Sickness 50 mg 59779-0198-02 | CVS | 12 tablets | — | — | FDA listed | — |
| Dramamine Original Formula 50 mg 63029-0901-01 | Medtech | 36 tablets | — | — | FDA listed | — |
| Motion Sickness Relief 50 mg 63941-0198-02 | Valu | 12 tablets | — | — | FDA listed | — |
| Motion Sickness Relief 50 mg 67091-0118-12 | WinCo | 12 tablets | — | — | FDA listed | — |
| Motion Sickness Relief 50 mg 69168-0408-86 | Allegiant | 12 tablets | — | — | FDA listed | — |
| Dimenhydrinate 50 mg 69842-0206-12 | CVS | 12 tablets | — | — | FDA listed | — |
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & generic status
🏛️
1992
On the market since
Dec 1992
📍
2026
Currently FDA-listed
34 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
🗺️ Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 46122-0536-53, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
210
Units reimbursed last 4 qtrs
2.5K
Gross reimbursed last 4 qtrs
$1.3K
Avg / prescription
$6.22
Avg / unit
$0.5244
Latest quarter Q4 2025
105Rx
Medicaid pays / ea
$0.5244
gross reimbursed
vs
NADAC / ea
$0.0575
acquisition cost
=
Spread
+$0.4669
+812% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
Fee-for-service · 73 Rx Managed care · 137 Rx
State Medicaid map
Units reimbursed · per 100k residents
4.314.9
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
📊 Medicare Part D spend CMS · PART D · 2025 (Q1-Q4)
Medicare Part D (outpatient prescription) spending for Dimenhydrinate (matched by generic name) — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Dimenhydrinate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Total Part D spend
$4K
Claims incl. refills
15
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$269.22
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
🔬 Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Motion Sickness Relief (this brand).
Top reported reactions
Age at onset
Reporter sex
Male · 33%
Female · 66%
Unknown · 0%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 46122-0536-53 You're viewing this | 2 BLISTER PACK in 1 CARTON (46122-536-53) / 6 TABLET in 1 BLISTER PACK | 1992-12-01 | Active |
📄 FDA label — Drug Facts FDA SPL
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage
⏱️ Dosage and Administration
⚠️ Warnings
📦 Storage and Handling
🧪 Active Ingredient
🧪 Inactive Ingredients
🎯 Purpose
🎯 Indications and Usage ▾
Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness
⏱️ Dosage and Administration ▾
Directions to prevent motion sickness, the first dose should be taken one-half to one hour before starting activity adults and children 12 years and over 1 to 2 tablets every 4-6 hours; do not exceed 8 tablets in 24 hours, or as directed by a doctor children 6 to under 12 years ½ to 1 tablet every 6-8 hours; do not exceed 3 tablets in 24 hours, or as directed by a doctor children 2 to under 6 years ½ tablet every 6-8 hours; do not exceed 1½ tablets in 24 hours, or as directed by a doctor
⚠️ Warnings ▾
Warnings Do not use for children under 2 years of age unless directed by a doctor. Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers. When using this product marked drowsiness may occur avoid alcoholic beverages alcohol, sedatives, and tranquilizers may increase drowsiness use caution when driving a motor vehicle or operating machinery If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
📦 Storage and Handling ▾
Other information each tablet contains: calcium 35 mg TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F) protect from moisture see end flap for expiration date and lot number
🧪 Active Ingredient ▾
Active ingredient (in each tablet) Dimenhydrinate 50 mg
🧪 Inactive Ingredients ▾
Inactive ingredients croscarmellose sodium, dibasic calcium phosphate dihydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, stearic acid
🎯 Purpose ▾
Purpose Antiemetic
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.